Title and Organization:
Mark J. Ahn, Ph.D. is Vice President of Abeona Therapeutics. He is also a Professor (adjunct) at Portland State University and Carnegie Mellon University. He joined Abeona from Pukana Partners, a strategic consulting firm for life science companies where he served as Principal. Mark's 20 year career has spanned small and large biopharmaceutical companies and academia. Most recently, he served as President and Chief Executive Officer, and Director of Galena Biopharma. He was formerly President, Chief Executive Officer, and Director of RXi Pharmaceuticals. Prior to RXi, Mark was an Associate Professor, Global Management at Atkinson Graduate School of Management, Willamette University. Previously, he served as Chair, Science & Technology Management, Victoria University at Wellington, New Zealand. Mark was also founder, President, and Chief Executive Officer of Hana Biosciences. Mark was also founder, President, and Chief Executive Officer of Hana Biosciences. Prior to Hana, he served as Vice President of Hematology and corporate officer at Genentech, Inc., as well as held positions of increasing responsibility at Amgen and Bristol-Myers Squibb Company; and served in the US Army. Mark also serves on public and venture capital-backed Board of Directors for Access Pharmaceuticals, Mesynthes and Scribes STAT. Dr. He is the author of over 50 peer reviewed journal articles and books, including Building the Case for Biotechnology. Mark received a BA and MBA from Chaminade University and his MA from Victoria University. He was a graduate fellow in Economics at Essex University, and obtained a Ph.D. from the University of South Australia. Dr. Ahn is a 2001 Henry Crown Fellow and member of the Aspen Global Leadership Network at the Aspen Institute.